India’s leading private life insurer, SBI Life Insurance, has posted another year of resilient performance in FY26, maintaining mid-teen growth and healthy margins even as it navigated regulatory changes and market challenges.The company reported 13.3% year-on-year growth in Annualised Premium Equivalent (APE) to around ₹24,270 crore.
Value of New Business (VNB) rose 12% to ₹6,670 crore, with the VNB margin holding steady at 27.5% — within the guided 26-28% range. This came despite absorbing the impact of GST changes on margins, which the firm offset through better product mix and operational efficiency rather than cutting commissions.
Embedded Value grew 15% to approximately ₹80,800 crore, supported by a core operating Return on Embedded Value (RoEV) of nearly 19-20%. The company continued to diversify its business, with stronger growth in non-banca channels and notable progress in retail protection and annuity segments — areas where it has traditionally lagged peers.Analysts highlight SBI Life’s robust business moats, including its strong bancassurance tie-up with State Bank of India, efficient cost structure, and improving product mix.
While the share of ULIPs remains relatively high, the company is gradually shifting towards higher-margin protection and annuity products.Despite this solid execution and a track record of consistent value creation, the stock trades at an attractive valuation of around 1.7-2.1x FY28E Embedded Value. Several brokerages remain constructive, citing industry-leading RoEV and the potential for further improvement in protection mix and sum assured.One leading brokerage has retained its BUY rating with a revised target price of ₹2,345, based on 2.1x FY28E EV.
It models 15% APE growth for FY27 and FY28, with VNB margins at 28-28.5%. Most adverse regulatory impacts from recent years — including changes to surrender values and tax exemptions — have now been largely absorbed.Risks remain, including any fresh regulatory tightening or shifts in distribution norms. Overall, analysts believe the current valuation underestimates SBI Life’s long-term compounding potential in India’s growing insurance sector.
